Summary of SKYE Earnings Call (Q4 2025)

1Key Financial Results and Metrics

SKYE ended Q4 2025 with $25.7 million in cash, cash equivalents, and short-term investments.

The company is managing its operating plan to extend its runway through Q4 2026.

2Strategic Updates and Business Highlights

Nimacimab Development: The company has made significant progress with nimacimab, particularly in the CBeyond program, which aims to evaluate nimacimab in combination with GLP-1 therapies for obesity treatment.

Clinical Data: Nimacimab demonstrated a 3% improvement in weight loss over semaglutide alone at 26 weeks, with a 22.3% mean weight loss observed in the combination arm after 52 weeks.

Expansion Study: SKYE announced an expansion of the CBeyond study to include higher intravenous doses (400 mg and 600 mg) to generate safety and pharmacokinetic (PK) data.

Collaboration with Halozyme: A partnership was established to develop a co-formulation of nimacimab using ENHANZE technology, aiming for high-volume subcutaneous injections in future studies.

Antibody Peptide Conjugate Program: Early data from this program shows promising potential for combining nimacimab with GLP-1 receptor agonists, achieving weight loss comparable to daily dosing regimens.

3Forward Guidance and Outlook

SKYE plans to report interim data from the CBeyond extension study in Q1 2026 and expects to finalize the Phase IIb study design by Q4 2026.

The company aims to clarify dose selection and establish a practical subcutaneous delivery method before advancing to Phase IIb trials.

4Challenges and Points of Concern

Dosing Concerns: There is ongoing evaluation regarding whether the current higher doses (400 mg and 600 mg) are sufficient, with discussions about potentially exploring even higher doses.

Regulatory Feedback: While the FDA provided constructive feedback on the Phase IIb design, the company must ensure that the clinical data supports its regulatory strategy.

Market Competition: The anti-obesity medication landscape is becoming increasingly crowded and price-compressed, which may impact nimacimab's positioning as a second-line therapy.

5Notable Q&A Insights

Higher Dose Cohorts: Analysts inquired about the rationale for the selected higher doses and the potential for exploring even higher doses, with management indicating confidence in the current dosing strategy while remaining open to further evaluation.

Formulation Work: There was clarification on the use of IV formulations in the expansion study versus subcutaneous delivery methods, with management emphasizing the need for rapid data generation.

Monotherapy vs. Combination Therapy: Questions arose regarding the efficacy of nimacimab in different peripheral tissues and how this might differ between monotherapy and combination therapy, with management indicating that adipose tissue and liver are critical for efficacy.

Future Development: The antibody peptide conjugate program was discussed as a long-term opportunity, with management highlighting its potential to improve dosing convenience and therapeutic outcomes. Overall, SKYE is making significant strides in its clinical programs, particularly with nimacimab, while navigating challenges related to dosing, regulatory expectations, and market competition.